Cost-effectiveness of tisotumab vedotin as a second- or third-line therapy for cervical cancer.

Saved in:

Bibliographic Details
Title:	Cost-effectiveness of tisotumab vedotin as a second- or third-line therapy for cervical cancer.
Authors:	Gengwei Huo^1,2,3,4, Wenjie Liu^1,2,3,4, Peng Chen^1,2,3,4 chenpengdoc@sina.com
Source:	Journal of Gynecologic Oncology. Sep2024, Vol. 35 Issue 5, p1-12. 12p.
Database:	Academic Search Ultimate

Description
ISSN:	20050380
DOI:	10.3802/jgo.2024.35.e58